Treating repair-deficient tumors with TDP1 inhibitors will most likely keep the toxicity and side effects of anticancer treatment at a minimum, since the non-tumor cells in the body will not be repair-deficient and presumably more resistant to drug treatment. This evidence concerns the gene TDP1 and neoplasm.